drugset / Trial / NCT01911611

A Study of RO6870868 in Healthy Volunteers

NCT01911611 ↗

Phase 1 Completed 60 enrolled Hoffmann-La Roche
RandomizedParallel-groupDouble-blindOther

Summary

This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics of RO6870868 in healthy volunteers. Subjects will be randomized to receive single ascending doses of either RO6870868 or placebo, with or without food.

Timeline

Start
2013-08
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject RO6870868 Unknown — —

Indications

No indication recorded.